Your browser doesn't support javascript.
loading
Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Shi, Wenyu; Lu, Tingxun; Xu-Monette, Yidan; Young, Ken H.
Affiliation
  • Shi W; Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • Lu T; Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • Xu-Monette Y; Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • Young KH; Division of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Chin Clin Oncol ; 13(1): 17, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38073311

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell / Lymphoma, Extranodal NK-T-Cell / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: Chin Clin Oncol Year: 2024 Document type: Article Affiliation country: United States Country of publication: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell / Lymphoma, Extranodal NK-T-Cell / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: Chin Clin Oncol Year: 2024 Document type: Article Affiliation country: United States Country of publication: China